X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Sensex Opens Firm; HDFC Bank Gains on Good Q2 Result
Mon, 22 Oct 09:30 am | Rini Mehta, TM Team

Asian stocks are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 3.8% while the Hang Seng is up 1.9%. The Nikkei 225 is trading down by 0.3%. The US benchmark S&P 500 index edged lower on Friday as strong earnings from Procter & Gamble Co were offset by ongoing concerns about rising interest rates and tensions over trade policy denting economic growth.

Back home, India share markets have opened the day on positive note. The BSE Sensex is trading up by 188 points while the NSE Nifty is trading up by 50 points. The BSE Mid Cap index opened the down by 0.7% while BSE Small Cap index opened the day up by 0.2%.

Barring information technology stocks and realty stocks, all sectoral indices have opened the day in green with FMCG stocks and metal stocks witnessing maximum buying interest.

The rupee is trading at Rs 73.37 against the US$.

Pharma stocks opened the day on a mixed note with Orchid Pharma and Biocon Ltd leading the gainers. As per an article in a leading financial daily, the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorisation of Lupin product NaMuscla. It is used for the symptomatic treatment of non-dystrophic myotonic (NDM) disorders.

Reportedly, the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the EMA, has adopted a positive opinion recommending the marketing authorisation of NaMuscla (mexiletine hydrochloride).

--- Advertisement ---
How to Survive This Stock Market Crash?

The market has entered a meltdown mode. Many wonder, what happens next?

Today we're going to show you how one could survive this Market Crash and even take advantage of it using our small cap stocks recommendation service.

We must say … this is a perfect time to get rich from this proven strategy.

Click here to learn more.
------------------------------

NaMuscla is a product of Lupin Neurosciences, a specialty pharma division of the company.

The CHMP's positive opinion will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU).

If approved, NaMuscla will be the first treatment licensed throughout the EU for the symptomatic treatment of myotonia in adults with NDM disorders.

According to IQVIA, a pharma consulting and research company, the largest proportion of new medicines launched in the last five years has been speciality drugs.

Here's an excerpt of what Research Analyst, Kunal Thanvi wrote about this segment recently,

  • "Going forward, speciality medicines will drive spending in developed markets.

    Indian pharma companies have been investing in their global speciality business for the last few years.

    Through this initiative, the pharma industry is trying to gradually move up in the value chain.

    However, this will entail significant front-ended investments. The corresponding revenue will accrue over a period of time."

Lupin share price opened the day up by 1.5%.

To know more about the company, you can access to Lupin's Q1FY19 result analysis and Lupin's 2017-18 Annual Report Analysis on our website.

Moving on to the news from banking sector. HDFC Bank's second-quarter FY19 net profit rose 20.6% on the back of higher net interest income and other income.

The bank posted a net profit Rs 50.1 billion for the three months ended 30th September, compared with Rs 41.5 billion in the year-ago period.

Net interest income increased 20.6% to Rs 117.6 billion, from Rs 97.5 billion in the corresponding period last year.

Other income, which includes core fee income, rose 11.4% to Rs 40.2 billion during the period, from Rs 36.1 billion a year ago.

Gross non-performing assets (NPAs), as a percentage of total advances, were at 1.33% in the September quarter, against 1.33% in the June quarter and 1.26% a year ago.

Provisions during the quarter increased 23.3% to Rs 18.2 billion, against Rs 14.8 billion in the year-ago quarter. In the April-June quarter, the bank had set aside Rs 16.3 billion in provisions.

Post-provision, the net NPA ratio was at 0.40% against 0.41% in the April-June quarter, and 0.43% in the year-ago quarter.

Interestingly, HDFC Bank has enjoyed the distinction of being the bank with the most premium valuation for nearly two decades. For over 60 quarters, the bank has declared results which showed loan book growing over 18% YoY, net interest margins between 3.8% and 4.2% and net NPAs below 1%.

Irrespective of the rate of GDP growth, inflation and interest rates, the bank never bothered to bring big variations in operating performance.

Consistency in Valuations Over Two Decades

It happily let go of market share in risky assets and never appeased big corporate borrowers. The consistency in the valuations of the bank is something investors will have to be watchful about in coming years.

HDFC Bank share price opened the day up by 1.5%.

To know what's moving the Indian stock markets today, check out the most recent share market updates here.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Equitymaster requests your view! Post a comment on "Sensex Opens Firm; HDFC Bank Gains on Good Q2 Result". Click here!

  

Stock Market Updates

GUJ. STATE PETRONET Surges by 5%; BSE OIL & GAS Index Up 0.1% (Today's Market)

Jan 18, 2019 09:42 AM

GUJ. STATE PETRONET share price has surged by 5% and its current market price is Rs 187. The BSE OIL & GAS is up by 0.1%. The top gainers in the BSE OIL & GAS Index is GUJ. STATE PETRONET (up 5.5%). The top losers are OIL INDIA LTD. (down 0.1%) and HPCL (down 0.6%).

SUN PHARMA Plunges by 10%; BSE HEALTHCARE Index Down 1.8% (Today's Market)

Jan 18, 2019 09:30 AM

SUN PHARMA share price has plunged by 10% and its current market price is Rs 426. The BSE HEALTHCARE is down by 1.8%. The top gainers in the BSE HEALTHCARE Index are CAPLIN POINT (up 1.7%) and ABBOTT INDIA (up 0.9%). The top losers is SUN PHARMA (down 10.1%)..

SUN PHARMA ADV. RES. Plunges by 7%; BSE 500 Index Down 0.0% (Today's Market)

Jan 18, 2019 09:28 AM

SUN PHARMA ADV. RES. share price has plunged by 7% and its current market price is Rs 173. The BSE 500 is down by 0.0%. The top gainers in the BSE 500 Index are CROMPTON GREAVES CONSUMER ELEC. (up 3.5%) and TV TODAY NETWORK (up 2.1%). The top losers are SUN PHARMA ADV. RES. (down 6.5%) and CYIENT LTD (down 5.5%).

RALLIS Plunges by 5%; BSE 500 Index Flat (Today's Market)

Jan 18, 2019 09:28 AM

RALLIS share price has plunged by 5% and its current market price is Rs 169. The BSE 500 is down by 0.0%. The top gainers in the BSE 500 Index are CROMPTON GREAVES CONSUMER ELEC. (up 3.5%) and TV TODAY NETWORK (up 2.1%). The top losers are RALLIS (down 5.2%) and CYIENT LTD (down 5.5%).

SUN PHARMA Plunges by 10%; BSE HEALTHCARE Index Down 1.6% (Today's Market)

Jan 18, 2019 09:24 AM

SUN PHARMA share price has plunged by 10% and its current market price is Rs 426. The BSE HEALTHCARE is down by 1.6%. The top gainers in the BSE HEALTHCARE Index are NATCO PHARMA (up 1.9%) and SYNGENE INTERNATIONAL (up 1.6%). The top losers is SUN PHARMA (down 10.0%)..

Global Stock Market Drivers; HUL, Reliance Industries Q3FY19 Results and Top Stocks in Action Today (Today's Market)

Jan 18, 2019 Pre-Open

Global stock market drivers, Key Q3 results, oil prices, and top stocks to guide the markets today.

View More Indian Share Market News

Most Popular

Our First Bluechip Stock Recommendation in Smart Money Secrets(The 5 Minute Wrapup)

Jan 9, 2019

For the first time, we have recommended a bluechip stock in Smart Money Secrets.

3 Stocks in Super Investor Sumeet Nagar's Portfolio That You Can Buy Right Now(The 5 Minute Wrapup)

Jan 11, 2019

The reasons that make these six stocks in Sumeet Nagar's portfolio so compelling

The Biggest Trend That I'm Seeing in the Market Today(The 5 Minute Wrapup)

Jan 10, 2019

For the first time ever, a majority of Indian households, will start to benefit from stock market wealth.

My First Stock Trading Recommendation For 2019(Profit Hunter)

Jan 10, 2019

My first trading recommendation for 2019 is a bluechip auto stock. Find out everything about it right away.

A Proven Super Investor Can Lead to Great Wealth(Profit Hunter)

Jan 7, 2019

Following a super investor can certainly help build a portfolio that can create significant wealth in the long term.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE SENSEX


Jan 18, 2019 10:37 AM

MARKET STATS